491595-36-9 Usage
Uses
Used in Organic Synthesis:
(2'-Methyl-[1,1'-biphenyl]-4-yl)boronic acid is used as a reagent in Suzuki-Miyaura cross-coupling reactions to form carbon-carbon bonds. Its presence allows for the efficient formation of these bonds, which is crucial in the synthesis of complex organic molecules.
Used in Pharmaceutical Research:
(2'-Methyl-[1,1'-biphenyl]-4-yl)boronic acid is used as a building block in the synthesis of biologically active compounds. Its unique structure and reactivity make it a valuable component in the development of new pharmaceuticals and agrochemicals.
Used in the Development of New Pharmaceuticals:
(2'-Methyl-[1,1'-biphenyl]-4-yl)boronic acid is employed as a key intermediate in the synthesis of novel drug candidates. Its ability to form carbon-carbon bonds and its compatibility with various organic compounds contribute to the creation of innovative and effective pharmaceuticals.
Used in the Development of Agrochemicals:
(2'-Methyl-[1,1'-biphenyl]-4-yl)boronic acid is utilized in the synthesis of agrochemicals, such as pesticides and herbicides. Its reactivity and structural features enable the development of new and improved agrochemicals with enhanced efficacy and selectivity.
Check Digit Verification of cas no
The CAS Registry Mumber 491595-36-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,9,1,5,9 and 5 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 491595-36:
(8*4)+(7*9)+(6*1)+(5*5)+(4*9)+(3*5)+(2*3)+(1*6)=189
189 % 10 = 9
So 491595-36-9 is a valid CAS Registry Number.
491595-36-9Relevant academic research and scientific papers
CRYSTALLINE AND SALT FORMS OF AN ORGANIC COMPOUND AND PHARMACEUTICAL COMPOSITIONS THEREOF
-
, (2020/07/14)
Provided herein are various salts, including tris(hydroxymethyl)aminomethane salts and sodium salts, as well as various crystalline forms of the compound represented by the structural formula: Also provided are pharmaceutical compositions comprising these salts and crystalline forms, methods for their manufacture, and uses thereof for treating conditions, including but not limited to conditions that would benefit from inhibition of dihydroorotate dehydrogenase (DHODH).
